FDA Proposes Removal of Oral Phenylephrine from OTC Medications

Overview of the Proposal

In recent developments, the U.S. Food and Drug Administration (FDA) has proposed the removal of oral phenylephrine from over-the-counter (OTC) medications intended for nasal congestion. The agency has determined that oral phenylephrine does not perform as effectively as claimed for alleviating nasal congestion. Consequently, they are urging consumers to seek alternative safe and effective relief options.

Findings on Oral Phenylephrine

The FDA’s review of existing data has concluded that oral phenylephrine is ineffective as a nasal decongestant. This decision is based on its efficacy rather than safety concerns. The agency conducted an extensive analysis, including historical data from its 1994 approval and recent studies, such as environmental exposure unit studies and new clinical trials. The objective was to evaluate whether earlier findings remained valid in light of contemporary research.

A significant finding from this review was the method used to measure nasal congestion. Older studies primarily relied on “nasal airway resistance” (NAR), which gauges airflow. However, the FDA now acknowledges that patient-reported symptom scores provide a more accurate representation of congestion relief. NAR measurements are complex and variable, lacking strong evidence that improvements correlate with actual symptom relief. This realization suggests that the original approval of oral phenylephrine may have been based on flawed data, prompting the current proposal for its removal.

FDA Statement

“It is the FDA’s role to ensure that drugs are safe and effective,” stated Patrizia Cavazzoni, M.D., Director of the FDA’s Center for Drug Evaluation and Research (CDER), in a recent news release. “Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant.”

Understanding Phenylephrine

What is Phenylephrine?

Phenylephrine is a widely used ingredient in many OTC cold and allergy medications designed to relieve nasal congestion. It may appear as the sole active ingredient in some products or in combination with others, such as acetaminophen for pain relief or dextromethorphan for cough suppression. It is essential to understand that removing phenylephrine from these combination products will not affect how the other active ingredients function.

Phenylephrine acts by constricting blood vessels in the nasal passages. It specifically targets alpha-1 adrenergic receptors on blood vessel walls, leading to reduced blood flow to the nasal tissues and decreased swelling. This reduction in swelling facilitates easier breathing.

Impact on Products

The FDA’s announcement specifically concerns oral phenylephrine, including pills and liquids, but does not extend to nasal sprays containing the ingredient. Some medications contain only phenylephrine, while others combine it with other active substances. This action focuses solely on the phenylephrine component.

Next Steps in the Proposal

Public Comment and Future Actions

As this is currently a proposal and not a final decision, the FDA is soliciting public comments regarding the recommendation. Should the FDA issue a final order, manufacturers will be required to either reformulate or eliminate products containing oral phenylephrine as a nasal decongestant.

Advice for Consumers

What Should Consumers Do?

Consumers should stay informed about this potential change. It is vital to always read the Drug Facts label to understand the ingredients in medications. If there are any questions regarding alternative treatments for nasal congestion, it is advisable to consult a doctor or pharmacist for guidance.